Aripiprazole

Reimbursement reviews of drugs later in the life cycle include a comprehensive assessment of clinical value, unmet clinical need, distinct social and ethical considerations, economic considerations, and impacts on the health systems. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial drug plans and cancer agencies. This review assesses Aripiprazole, 2 mg to 15 mg per day administered orally Indication under consideration for reimbursement: Adjunct to antidepressants for the treatment of major depressive disorder in adult patients who had an inadequate response to at least 1 prior antidepressant treatment.